{"title":"Estimating the Timeframe of Lactate Reduction in Acute Cardiovascular Disease Using Functional Data Analysis Based on Nonlinear Mixed Effects Models.","authors":"Takaya Nakashima, Shuntaro Sato, Hidetoshi Matsui, Atsushi Mizuno","doi":"10.1536/ihj.23-659","DOIUrl":null,"url":null,"abstract":"<p><p>In patients with acute cardiovascular disease, treatment aimed at reducing lactate levels is crucial for improving prognosis. Trends in blood lactate levels for each specific cardiovascular disease can provide an accurate evaluation of the patient's condition. We used functional data analysis with nonlinear mixed effects models to estimate the timeframe of lactate reduction in 3 cardiovascular diseases (acute heart failure, aortic dissection, and ischemic heart disease) by analyzing lactate trends.Among 1,816 patients admitted to the intensive care unit (ICU) or intensive cardiovascular care unit (ICCU) of St. Luke's International Hospital for cardiology or cardiovascular surgery from December 31, 2010, to June 31, 2020, 1,249 adults with a diagnosis of acute heart failure (39%), aortic dissection (24%), or ischemic heart disease (37%) were included in the present study. Using functional data analysis with nonlinear mixed effects models, our study estimated the timeframe of lactate reduction based on blood lactate level trends. Lactate reduction took 30 hours (95% CI, 23-37 hours) in patients with acute heart failure, 40 hours (95% CI, 33-47 hours) in patients with aortic dissection, and 95 hours (95% CI, 49-failed estimate) in patients with ischemic heart disease.We were able to estimate the timeframe of lactate reduction with different cardiovascular diseases. Recognizing the differences in lactate reduction may be useful in developing treatment plans tailored to each disease.</p>","PeriodicalId":13711,"journal":{"name":"International heart journal","volume":"65 6","pages":"1058-1065"},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International heart journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1536/ihj.23-659","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
In patients with acute cardiovascular disease, treatment aimed at reducing lactate levels is crucial for improving prognosis. Trends in blood lactate levels for each specific cardiovascular disease can provide an accurate evaluation of the patient's condition. We used functional data analysis with nonlinear mixed effects models to estimate the timeframe of lactate reduction in 3 cardiovascular diseases (acute heart failure, aortic dissection, and ischemic heart disease) by analyzing lactate trends.Among 1,816 patients admitted to the intensive care unit (ICU) or intensive cardiovascular care unit (ICCU) of St. Luke's International Hospital for cardiology or cardiovascular surgery from December 31, 2010, to June 31, 2020, 1,249 adults with a diagnosis of acute heart failure (39%), aortic dissection (24%), or ischemic heart disease (37%) were included in the present study. Using functional data analysis with nonlinear mixed effects models, our study estimated the timeframe of lactate reduction based on blood lactate level trends. Lactate reduction took 30 hours (95% CI, 23-37 hours) in patients with acute heart failure, 40 hours (95% CI, 33-47 hours) in patients with aortic dissection, and 95 hours (95% CI, 49-failed estimate) in patients with ischemic heart disease.We were able to estimate the timeframe of lactate reduction with different cardiovascular diseases. Recognizing the differences in lactate reduction may be useful in developing treatment plans tailored to each disease.
期刊介绍:
Authors of research articles should disclose at the time of submission any financial arrangement they may have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product. Such information will be held in confidence while the paper is under review and will not influence the editorial decision, but if the article is accepted for publication, the editors will usually discuss with the authors the manner in which such information is to be communicated to the reader.